Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Fig. 4

Baseline biomarker results from clinico-genomic data based on RECIST response. A Patient age, IHC results, germline (according to routine clinical diagnostic testing) and somatic BRCA mutation status, clinical characteristics, and prior therapies are depicted. Data were available for 46 patients with at least one postbaseline efficacy assessment. Samples were taken at baseline before study treatment. B-C ORR grouped by somatic BRCA1 mutation and PD-L1 expression. D Correlation between CD8 status and PD-L1 expression. IHC, immunohistochemistry; ORR, objective response rate; NA, not available

Back to article page

Molecular Cancer

ISSN: 1476-4598